BioCryst Pharmaceuticals (NASDAQ: BCRX) is one of 286 public companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its peers? We will compare BioCryst Pharmaceuticals to related companies based on the strength of its valuation, profitability, analyst recommendations, dividends, risk, institutional ownership and earnings.

Risk and Volatility

BioCryst Pharmaceuticals has a beta of 3.07, suggesting that its stock price is 207% more volatile than the S&P 500. Comparatively, BioCryst Pharmaceuticals’ peers have a beta of 6.78, suggesting that their average stock price is 578% more volatile than the S&P 500.

Profitability

This table compares BioCryst Pharmaceuticals and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
BioCryst Pharmaceuticals -167.58% -123.16% -38.71%
BioCryst Pharmaceuticals Competitors -5,425.42% -213.63% -38.24%

Institutional & Insider Ownership

84.7% of BioCryst Pharmaceuticals shares are owned by institutional investors. Comparatively, 49.7% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 5.8% of BioCryst Pharmaceuticals shares are owned by insiders. Comparatively, 17.5% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and target prices for BioCryst Pharmaceuticals and its peers, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioCryst Pharmaceuticals 0 4 6 0 2.60
BioCryst Pharmaceuticals Competitors 892 3286 11782 235 2.70

BioCryst Pharmaceuticals currently has a consensus price target of $9.14, indicating a potential upside of 86.21%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 42.62%. Given BioCryst Pharmaceuticals’ higher possible upside, analysts clearly believe BioCryst Pharmaceuticals is more favorable than its peers.

Earnings and Valuation

This table compares BioCryst Pharmaceuticals and its peers top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
BioCryst Pharmaceuticals $26.35 million -$55.14 million -7.67
BioCryst Pharmaceuticals Competitors $284.49 million $34.10 million 64.66

BioCryst Pharmaceuticals’ peers have higher revenue and earnings than BioCryst Pharmaceuticals. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Summary

BioCryst Pharmaceuticals peers beat BioCryst Pharmaceuticals on 8 of the 12 factors compared.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc. is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. The Company’s drug candidates include RAPIVAB, RAPIACTA, ALPIVAB, PERAMIFLU, Avoralstat, BCX7353, other second generation hereditary angioedema (HAE) compounds, Galidesivir and Forodesine. Its product RAPIVAB contains peramivir. ALPIVAB is an intravenous neuraminidase inhibitor. Galidesivir is a broad-spectrum antiviral (BSAV) research program developed for the treatment of hemorrhagic fever viruses. Forodesine is a Purine Nucleoside Phosphorylase (PNP) inhibitor in development by Mundipharma as a treatment for cancer.

Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.